BridgeBio Pharma (BBIO) Insider Dachille Buys 3,990 Shares

Douglas Dachille recently purchased 3,990 shares of BridgeBio Pharma, Inc. (NasdaqGS: BBIO) on June 22, 2026. This insider buying activity comes as the company's shares traded near $68.63 on Thursday.

Insider Buying and Selling at BridgeBio Pharma, Inc.

Douglas Dachille's acquisition of 3,990 shares wasn't part of a pre-planned trading program. Other recent insider activities include Jennifer Cook's purchase of 37,167 shares at an average price of $12.28, followed by sales on June 24, 2026, and Hannah Valantine's planned sale of 2,196 shares at $68.57 on June 23, 2026.

Other Institutional Activity in BridgeBio Pharma

Several institutional investors have been active in BridgeBio Pharma. BlackRock, Inc. trimmed its holdings by 341,772 shares, leaving it with 14,207,757 shares valued at approximately $1.05 billion. Janus Henderson Group PLC increased its stake by 2,178,556 shares, bringing its total to 13,179,013 shares worth around $978.6 million, a 19.8% increase. Viking Global Investors LP reduced its position by 2,551,500 shares, now holding 11,842,434 shares valued at $879.4 million, marking a 17.7% decrease.

BridgeBio Pharma, Inc. Stock Up 2.2%

On Thursday, BridgeBio Pharma's stock traded near $68.63. The company has a market capitalization of about $13.5 billion and a forward P/E ratio of 130.71. Its beta is 0.975, indicating moderate volatility compared to the market. The 52-week range for the stock is between $41.30 and $84.94, with moving averages of $69.67 for 50 days and $67.55 for 200 days.

Analysts Set New Price Targets

Several analysts have recently weighed in on BridgeBio Pharma. On June 16, 2026, Mizuho maintained a buy rating with a price target of $96. Canaccord Genuity initiated coverage with a buy rating and a $104 target on June 3, 2026. The consensus among analysts is a strong buy, with an average price target of $102.28 based on 23 analyst opinions.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing medicines for genetic diseases. Based in Palo Alto, California, the company works on treatments for conditions like cardiomyopathy and amyloidosis. Under the leadership of CEO Dr. Neil Kumar, BridgeBio also explores therapies for oncology and gene therapy diseases.

Bottom Line

Douglas Dachille's recent purchase of shares in BridgeBio Pharma highlights ongoing insider interest in the company. As a biopharmaceutical firm, BridgeBio is actively involved in developing treatments for genetic diseases, which investors closely monitor. The company's stock performance and analyst ratings suggest continued attention from the market.